)
)
OSE Immunotherapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from OSE Immunotherapeutics SA
Access all reports
OSE Immunotherapeutics SA is a French biotechnology company focused on developing immunotherapies for cancer, autoimmune diseases, and infectious diseases. The company’s pipeline includes innovative treatments aimed at modulating the immune system, including checkpoint inhibitors, therapeutic vaccines, and monoclonal antibodies. OSE Immunotherapeutics leverages proprietary technology platforms to design therapies that target specific immune pathways, with the goal of improving patient outcomes in conditions where immune response plays a critical role. The company collaborates with research institutions and pharmaceutical companies to advance its clinical programs. The company is headquartered in Nantes, France, and its shares are listed on Euronext Paris.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
OSE
Country
🇫🇷 France